Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
This phase II/III trial is studying the side effects and how well giving dasatinib together
with combination chemotherapy works in treating young patients with newly diagnosed acute
lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells.